Products for Research Use Only

SZM-1209

CAT: 0804-HY-149052-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-149052-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM) . SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects[1].
CAS Number
2919801-86-6
UNSPSC
12352005
Target
Mixed Lineage Kinase; Necroptosis; RIP kinase
Type
Reference compound
Related Pathways
Apoptosis; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/szm-1209.html
Solubility
10 mM in DMSO
Smiles
CCS(=O)(NC1CCC(CC1)C(NC2=NC3=C(S2)C=C(C(F)=C3)OC4=CC=C(C(NC(CC5=CC=CC(C(F)(F)F)=C5)=O)=C4)F)=O)=O
Molecular Formula
C31H29F5N4O5S2
Molecular Weight
696.71
References & Citations
[1]Zhang X, et al. Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway. J Med Chem. 2023 Apr 13;66 (7) :5261-5278.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1; RIPK3